These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25423927)

  • 1. [New Developments in CKD-MBD. New aspects in phosphate binders].
    Yokoyama K
    Clin Calcium; 2014 Dec; 24(12):1815-23. PubMed ID: 25423927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New Developments in CKD-MBD. Future perspective of calcimimetics].
    Mizobuchi M; Inoue T
    Clin Calcium; 2014 Dec; 24(12):1825-30. PubMed ID: 25423928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
    Hanafusa N
    Clin Calcium; 2015 May; 25(5):711-21. PubMed ID: 25926575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperphosphatemia and phosphate binders: effectiveness and safety.
    Kalaitzidis RG; Elisaf MS
    Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
    Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CKD-MBD: impact on management of kidney disease.
    Ogata H; Koiwa F; Kinugasa E; Akizawa T
    Clin Exp Nephrol; 2007 Dec; 11(4):261-268. PubMed ID: 18085385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?
    Oliveira RB; Cancela AL; Graciolli FG; Dos Reis LM; Draibe SA; Cuppari L; Carvalho AB; Jorgetti V; Canziani ME; Moysés RM
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):286-91. PubMed ID: 19965540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal use of phosphate binders in chronic kidney disease.
    Sonikian M; Papachristou E; Goumenos DS
    Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of phosphate binders in moderate CKD.
    Block GA; Wheeler DC; Persky MS; Kestenbaum B; Ketteler M; Spiegel DM; Allison MA; Asplin J; Smits G; Hoofnagle AN; Kooienga L; Thadhani R; Mannstadt M; Wolf M; Chertow GM
    J Am Soc Nephrol; 2012 Aug; 23(8):1407-15. PubMed ID: 22822075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.
    Wesseling-Perry K; Salusky IB
    Pediatr Nephrol; 2013 Apr; 28(4):617-25. PubMed ID: 23381010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of phosphate binders: a perspective on novel therapeutics.
    Cernaro V; Santoro D; Lucisano S; Nicocia G; Lacquaniti A; Buemi M
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1459-63. PubMed ID: 25243756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteo-renal regulation of systemic phosphate metabolism.
    Razzaque MS
    IUBMB Life; 2011 Apr; 63(4):240-7. PubMed ID: 21438115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.
    Cozzolino M; Brancaccio D
    Int J Artif Organs; 2007 Apr; 30(4):293-300. PubMed ID: 17520565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
    Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
    J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
    Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
    Phan O; Maillard M; Malluche HH; Stehle JC; Funk F; Burnier M
    Biomed Res Int; 2015; 2015():515606. PubMed ID: 26221597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.
    Cozzolino M; Bruschetta E; Cusi D; Montanari E; Giovenzana ME; Galassi A
    Expert Opin Pharmacother; 2012 Nov; 13(16):2337-53. PubMed ID: 23033914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New Developments in CKD-MBD. Strategies for the management of predilalysis CKD-MBD].
    Ando R
    Clin Calcium; 2014 Dec; 24(12):1845-51. PubMed ID: 25423931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.